Replication Study Planning

Partial Replicate Study A partial replicate study is a BE study design frequently used for drugs with high variability in pharmacokinetics (PK). It provides robust insights into intra-subject variability while ensuring compliance with regulatory requirements for BE studies. Key Features of a Partial Replicate Study 1. Study Design: Typically involves three periods (e.g., TRR, TRT, RTR), where each subject receives the test formulation (T) once and the reference formulation (R) twice. This design allows for a more accurate assessment of intra-subject variability. 2. Purpose: To evaluate the variability of both test and reference products. To establish BE using scaled bioequivalence criteria, particularly for highly HVDs with intra-subject variability >30%. 3. Regulatory Focus: Scaled bioequivalence uses widened acceptance limits for HVDs, improving the likelihood of demonstrating equivalence without compromising safety or efficacy. 4. Benefits: Provides robust data for variability assessment. Reduces subject numbers compared to fully replicated designs. Enhances the power to demonstrate bioequivalence for challenging drugs. Data Inference in Partial Replicate Studies: 1. Intra-Subject Variability Analysis: The design captures intra-subject variability for both T and R formulations, which is critical for understanding the differences in individual responses. 2. Scaled Bioequivalence (SABE): In cases of high variability (, CV > 30%), scaled bioequivalence is applied. The limits for bioequivalence (e.g., 80.00–125.00%) are widened proportionally based on the reference product’s variability. 3. Confidence Intervals (CI): 90% CIs for the test/reference ratios of PK parameters like Cmax and AUC are calculated and compared against scaled or standard BE limits to determine equivalence. 4. Detection of Outliers: Multiple dosing of the reference product helps identify and manage outliers in the data, ensuring reliable conclusions about bioequivalence. 5. Statistical Models: Mixed-effects models (e.g., ANOVA) are used to: Compare PK parameters of test and reference formulations. Quantify inter- and intra-subject variability. Identify sequence, period, or carryover effects that may influence results. 6. Variability Source Determination: The design distinguishes whether variability arises from the formulation, study methodology, or subject-specific factors, providing deeper insights into product performance. 7. Regulatory Decision-Making: If the reference product shows high variability, scaled bioequivalence ensures that inherent variability does not unjustly penalize the test product. Successful results imply that the test product can be inferred to have bioequivalence to the reference product. Applications Ideal for HVDs where traditional designs fail to demonstrate bioequivalence Used to establish robust and reproducible bioequivalence conclusions, ensuring product interchangeability in the market.

📊 TUTORIAL SERIES: The Bulk RNA-Seq Codex 👉 Session 02: Experimental Design — Where Discoveries Are Won or Lost Your pipeline can be flawless. Your DESeq2 model can be elegant. But if batch is confounded with condition, every "significant" gene is an artifact. Session 02 is now live at #MultiomeAcademy (https://lnkd.in/eCvx3E4G) the decisions you make before generating a single read determine everything downstream. Session 02 Highlights: 👉 The Replicates Truth: Schurch et al. showed 3 replicates detect only ~60% of true DE genes. At 6 replicates → 85%. At 12 → 95%. For human postmortem brain (CV 0.5–0.8), detecting a 1.5-fold change requires 42 samples per group — 6× more than cell lines. 👉 Power Analysis in R: Hands-on RNASeqPower code comparing iPSC neurons (CV 0.2) vs. mouse cortex (CV 0.4) vs. human postmortem brain (CV 0.6). Know your numbers before writing the grant. 👉 The Deadly Sin of Confounding: All controls in January, all treated in March = unsalvageable experiment. No ComBat, no SVA, no statistical method can rescue this. Prevention strategies, randomisation schemes, and a 5-method correction comparison table (model covariate → ComBat-seq → SVA → RUV → limma). 👉 Brain-Specific Design: Why 5–8 replicates are the minimum for postmortem cortex. PMI, agonal state, medication history, brain bank of origin as confounders. Ribo-depletion over poly(A) when RIN < 6. Planning for cell-type heterogeneity and deconvolution at the design stage — not after. 👉 Study Designs with Code: Simple, paired (tumor vs. adjacent normal for IDH1/EGFR/MGMT in gliomas), factorial (sex × disease interaction in AD), time-series (activity-dependent genes: FOS → ARC → BDNF), and multi-region (GTEx-style ~ donor + region). 📖 Core Thesis: The depth vs. replicates trade-off almost always favours replicates. Liu et al. (2014) showed that going from 3 → 5 replicates detects more DE genes than going from 10M → 30M reads with only 3 replicates. Budget for biology, not bytes. Read the Full Technical Guide 👇 https://lnkd.in/eTCiHZ9N THE SERIES ROADMAP: ✅ Session 01: Foundations of Transcriptomic Profiling [LIVE] ✅ Session 02: Experimental Design & Power Analysis [LIVE — TODAY] 👉 Session 03: Quality Control & Contamination Screening [TOMORROW] 📋 Sessions 04–09: [coming] #Bioinformatics #Genomics #Transcriptomics #RNASeq #ExperimentalDesign #PowerAnalysis #Biostatistics #Multiomics #DataScience #Biotech #LifeSciences #ComputationalBiology #NextGenerationSequencing #NGS #SystemsBiology #MolecularBiology #MultiomeAcademy #PostdocLife #PrecisionMedicine #SingleCellCodex #Biostats #Rstats #PythonForBiology #OpenScience #AcademicLinkedIn #python #R

Researchers often get stuck in the methods section. They overthink every detail, aiming for perfection. However, here’s the reality: Your methods aren't meant to be a masterpiece of writing. They're a template for others to replicate your study. I've reviewed hundreds of papers. The best methods sections? They're clear, concise, and replicable. Here's how to pull it off with yours: 1. Restate your research question ↳ Remind readers why you're doing this 2. Explain your chosen method ↳ Qualitative? Quantitative? Mixed? 3. Justify uncommon methods ↳ Used something new? Defend it. 4. Detail your data collection ↳ Surveys? Interviews? Be specific. 5. Describe your data analysis ↳ What tools or tests did you use? 6. Justify your methods ↳ Why these specific strategies? 7. Address challenges ↳ What problems did you face? How did you solve them? 8. Consider ethics ↳ How did you protect participants? Your one goal here is to help others replicate your study. Don't hide behind jargon. Use simple language. Be thorough. Your methods section is the heart of your research integrity. P.S. Struggling with other parts of your paper? Let me know in the comments. I've got tips for every section. Want the PDF of this image? Repost and leave a comment with more than 5 words and I'll send it to you. #research #phd #science

New chapter on replication studies in my free textbook https://lnkd.in/eB5B9udq  I discuss the difference between direct and conceptual replications, how to analyze them, why don't just do 1 study with alpha 0.0025, and how to deal with conflicting results across studies. I define a direct replication as a study where a researcher has the goal to not introduce variability in the effect size compared to the original study, while in a conceptual replication variability is introduced intentionally with the goal to test the generalizability. I hope this is helpful. Some approaches focus on a judgment of the similarity in operationalizations between studies, but as there are always differences, I think we should focus on what the researcher intends to test.   Then I discuss 3 approaches to analyze replication studies. A test of differences in effect sizes. Is the replication study significant? Is the effect (or the difference between effects) too small to matter? The first is too rarely done, but the most interesting. Then it becomes a bit niche, but I dive into why we do 2 studies with alpha = 0.05, and not just one study with alpha 0.05 * 0.05 = 0.0025. There is a bunch of non-statistical reasons (identifying systematic error).   Interestingly, it depends which of the 2 options is more efficient, in terms of that you need a smaller sample size. It does not matter a lot, but depending on the power, sidedness of the test, and effect size, either can be just a bit more efficient.   Then I discuss Many Labs 5 as an example of how difficult it is to predict if studies will replicate. It’s a great study showing researchers can’t predict whether moderators matter in replication studies. It shows we can only know is something replicates if we replicate it. I hope it will be a useful chapter to read through if you are thinking of doing replication research yourself, or if you want to teach about it to your students! https://lnkd.in/eB5B9udq We will also discuss this topic in the next 2 episodes of our podcast Nullius in Verba! 

Replication is not optional, it's foundational. Here I go again with another reason I often reject manuscripts without review as EIC. In plant pathology (and most fields), repeating experiments over time should be standard and planned in advance. Some authors overlook a basic requirement in our Instructions for the Authors: inform that the experiment was replicated at least once (eg. different times or locations) and how all data was incorporated into the analysis. It’s not enough to say an experiment was repeated; results must be analyzed as a whole. Use appropriate tools: include "experiment" as a factor and test for interactions, assess variance homogeneity, or apply mixed models or meta-analytic approaches. Selecting the “best” or most expected run undermines scientific rigor. Cost constraints are real, but not an excuse for poor design. Use efficient designs, pilot studies, power analysis, historical data, or collaboration to optimize resources. If full replication isn't feasible, justify and discuss limitations - transparency is always better than omission!